• To improve the understanding of renin-angiotensinaldosterone system (RAAS) blockade, its implications, and the interplay of RAAS activity and its blockade on cardiovascular, cerebral and renal protection, so as to strengthen scientific research. • To create medical education initiatives/projects which are needs driven, i.e. based on input from the group, for both doctors and patients, so as to raise the awareness of optimising RAAS suppression, in order to improve the outcomes for all. • The group, composed of experts from a broad range of specialities, strive to be scientific, credible and unbiased, so as to ensure physician and, where appropriate, patient uptake of findings.
From this issue on, the RAAS Working Group will publish reports in JRAAS, discussing and critically reviewing important RAAS-related topics. Each review will be accompanied by a short Editorial.
The Vitamin D is no longer considered a vitamin that is just necessary for healthy bones. Recently, numerous discoveries were made revealing novel pleiotropic effects of vitamin D signalling. It turned out that vitamin D exerts multiple effects on the cardiovascular (CV) system. 1,2 As a result, vitamin D receives considerable interest in the CV and renal community.
Vitamin D deficiency has been associated with adverse CV outcome, in patients with renal disease, 3 but also in patients with heart disease, 4,5 and even in subjects from the general population. 6 Second, our knowledge on vitamin D biology has exploded with the use of sophisticated molecular and genetic models, most notably mice lacking the vitamin D receptor. 1 The paper by Müller and colleagues 7 describes some of the most pertinent mechanisms by which vitamin D may exert its beneficial effects in CV disease. Specifically, vitamin D has been shown to be a negative regulator of renin, to be associated with a reduction in blood pressure and a reduction of left ventricular hypertrophy, to protect the kidney from nephropathy, and to act as an immunomodulator. Intervention studies testing (active) vitamin D or vitamin D receptor activators employing rodent models of renal and cardiac disease have suggested strong efficacy of these compounds.
So, epidemiological and experimental data clearly suggest that vitamin D supplementation should benefit subjects with increased CV risk. Furthermore, in patients with
